Novartis India Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Novartis India Ltd. from all sources in a single place.

16 Sep 2025

897.05

0.07%

Novartis' Vymada patent revoked, generics likely to cut prices by 70%

Business Standard

Novartis lost its Vymada patent in India, enabling generic drugmakers to launch versions that could slash prices by up to 70 per cent and improve access for cardiac patients

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

15 Sep 2025

897.05

0.07%

Novartis signs $5.7 bn licensing deal with Monte Rosa Therapeutics

Business Standard

Under the agreement, Monte Rosa will receive an upfront payment of $120 million and could earn milestone payments and royalties that lift the total value to as much as $5.7 billion

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

01 Aug 2025

897.05

0.07%

AGM

Novartis India Ltd - 500672 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

BSE India

Intimation of the Voting Results and the Scrutinizer''s Report for the Annual General Meeting of the Company held on Thursday, July, 2025.

pdf

Novartis India Ltd.

31 Jul 2025

897.05

0.07%

AGM

Novartis India Ltd - 500672 - Shareholder Meeting / Postal Ballot-Outcome of AGM

BSE India

Intimation of the proceedings of the 77th Annual General Meeting of the Company held on July 31, 2025, at 11 am IST through video conferencing mode

pdf

Novartis India Ltd.

30 Jul 2025

897.05

0.07%

Company Update

Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Intimation of the publication of Financial Results for the quarter ended June 30, 2025 in the Newspaper - Financial Express (English) and Navshakti (Marathi).

pdf

Novartis India Ltd.

29 Jul 2025

897.05

0.07%

Company Update

Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Intimation of the approval of the Board of Directors for the Appointment of Cost Auditor for the Financial Year 2025-26

pdf

Novartis India Ltd.

29 Jul 2025

897.05

0.07%

Result

Novartis India Ltd - 500672 - Unaudited Financial Results For The Quarter Ended As On June …

BSE India

Intimation for the Unaudited Financial Results for the Quarter ended as on June 30, 2025.

pdf

	Jun 2025	Mar 2025	Jun 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	98.16	94.51	102.70	3.9%	-4.4%
Operating Profit Qtr	27.24	23.91	23.97	13.9%	13.6%
Net Profit Qtr	27.62	29.30	25.74	-5.7%	7.3%
Earning Per Share Adjusted latest Qtr	11.19	11.87	10.42	-5.7%	7.4%

* Standalone data

Detailed Results

Novartis India Ltd.

29 Jul 2025

897.05

0.07%

Board Meeting

Novartis India Ltd - 500672 - Board Meeting Outcome for Intimation About The Outcome Of The …

BSE India

Intimation about the Outcome of the Board Meeting held on July 29, 2025, inter alia for the approval of the unaudited Financial Statements for the Quarter ending as on June 30, 2025.

pdf

Novartis India Ltd.

17 Jul 2025

897.05

0.07%

Novartis cannot block generic version of Entresto, judge rules

Business Line

The judge also reversed her prior ruling that Novartis would likely prove that MSN's tablets looked too similar to Entresto and would confuse consumers

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

14 Jul 2025

897.05

0.07%

Company Update

Novartis India Ltd - 500672 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Intimation of the Certificate dated July 10, 2025, received from RTA under Regulation 74(5) of SEBI (DP) Regulations, 2018

pdf

Is Novartis India Ltd. worth buying?

70 Votes:

Buy 74.29%

Sell 15.71%

Hold 10.0%